Dispersion composition

Abstract

To provide a composition containing Ji Xue Teng (Spatholobus suberectus) or an extract thereof, which exhibits superior temporal stability.SOLUTION: A dispersion composition comprises (a) Ji Xue Teng (Spatholobus suberectus) or an extract thereof, (b) a phospholipid, and (c) a polyhydric alcohol, where the mass ratio (b) / (a) is 0.01 or more and 8.0 or less.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to a dispersion composition. [Background technology]

[0002] Birdwood herb is made from the dried stems of Spatholobus suberectus, Mucuna birdwoodiana, Millettia nitida, or Millettia dielsiana, which are all members of the Leguminosae family, and the dried product or its extract is used in traditional Chinese medicine. It is used as a blood tonic, tonic, and analgesic for menstrual disorders, pain in the lower back and knees, rheumatism, and paralysis of the limbs.

[0003] Patent Document 1 describes a Japanese or Chinese herbal hair growth agent containing an active hair growth ingredient, which is prepared by soaking a mixture of herbs including ginseng, black beans, Polygonum multiflorum, Bones fat, Angelica acutiloba, Chicken blood wilt, Cnidium officinalis, Red sage, safflower, peach kernel, windbreaker, Madder root, and Oak leaf in 75% (V / V) ethanol and leaving it at a cold temperature of about 5°C to 10°C for 3 weeks to obtain an extract, and mixing this with a liquid obtained by extracting at a high temperature of about 75°C for 10 hours.

[0004] Patent Document 2 describes a skin cosmetic composition having excellent whitening effects, which contains one or more extracts of herbal medicines selected from Tung tree bark, Cockscomb Worm, Fringe of Fringe, and Yellow Exotic Plant.

[0005] Patent Document 3 describes cosmetics containing ethanol from Chinese cricket wort and having a high whitening effect, in particular lotions and creams containing an ethanol extract from Chinese cricket wort.

[0006] Patent Document 4 describes a composition for preventing or treating periodontal disease, which contains henbit or an extract thereof as an active ingredient. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] Patent No. 2648618 [Patent Document 2] Patent No. 3055816 [Patent Document 3] Japanese Patent Application Publication No. 5-97649 [Patent Document 4] Patent No. 5311008 Summary of the Invention [Problem to be solved by the invention]

[0008] When used directly in an aqueous solution, henbit or its extract is unstable and has the problem of precipitation over time. The problem to be solved by the present invention is to provide a dispersion composition of henbit or its extract that is excellent in stability over time. [Means for solving the problem]

[0009] The present invention encompasses the embodiments described below. Section 1. (a) henbit or its extract, (b) phospholipids, and (c) A dispersion composition comprising a polyhydric alcohol, the mass ratio of (b) / (a) being 0.01 or more and 8.0 or less. Section 2. Item 2. The dispersion composition according to item 1, wherein the (b) phospholipid contains lecithin. Section 3. Item 2. The dispersion composition according to item 1, wherein the (b) phospholipid contains lecithin that has not been substantially subjected to hydrogenation treatment. Section 4. Item 2. The dispersion composition according to item 1, wherein the (b) phospholipid contains lecithin having a phosphatidylcholine content of 1% by mass or more and 40% by mass or less. Section 5. 2. The dispersion composition according to item 1, wherein the (c) polyhydric alcohol includes a dihydric or trihydric alcohol. Section 6. 2. The dispersion composition according to item 1, wherein the (c) polyhydric alcohol comprises at least one selected from the group consisting of propylene glycol, butylene glycol, dipropylene glycol, glycerin, and diglycerin. Section 7. Item 2. The dispersion composition according to item 1, wherein the average particle size of the dispersed particles is 500 nm or less. Section 8. 8. The dispersion composition according to any one of items 1 to 7, which is an external preparation for skin. Section 9. 8. The dispersion composition according to any one of items 1 to 7, which is for use in a cosmetic preparation, an oral composition, or a hair growth agent. Section 10. Item 10. A drug comprising the dispersion composition according to item 8 or 9. Effect of the Invention

[0010] According to the present invention, it is possible to provide a dispersion composition containing henbit or an extract thereof, which has excellent stability over time. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] In this specification, the terms "contain," "include," and "have" are concepts that also encompass "consist essentially of" and "consist only of."

[0012] Hereinafter, an embodiment of the present invention will be described.

[0013] The present invention provides a dispersion composition comprising (a) sclerotinia gracilis or an extract thereof, (b) a phospholipid, and (c) a polyhydric alcohol, wherein the mass ratio of (b) / (a) is 0.01 or more and 8.0 or less.

[0014] Birdwood Worm is made by drying the stems of Spatholobus suberectus, Mucuna birdwoodiana, Millettia nitida, or Millettia dielsiana, which belong to the Leguminosae family, and can be obtained as a dried product from a supplier. An extract of Birdwood Worm can be produced by a known method including adding ethanol or an aqueous ethanol solution to Birdwood Worm and purifying it as necessary, or can be obtained from a supplier.

[0015] The content of (a) Angustifolia or an extract thereof in the dispersion composition is not particularly limited, but is, for example, 0.00002 to 5% by weight, and preferably 0.0002 to 2% by weight, calculated on a dry basis.

[0016] (b) Phospholipid has the effect of dispersing (a) Scutellaria or an extract thereof in the composition. Examples of phospholipid include glycerophospholipid and sphingophospholipid.

[0017] Glycerophospholipids are compounds having a glycerophosphate backbone and a fatty acid ester, a long-chain alkyl ether, or a vinyl ether as a lipophilic group, and examples thereof include phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphadiylinositol, phosphatidylinositol polyphosphate, phosphatidylglycerol, diphosphatidylglycerol (cardiolipin), phosphatidic acid, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylserine, lysophosphatidylinositol, lysophosphatidylglycerol, and lysophosphatidic acid.

[0018] Sphingophospholipids are compounds in which a long-chain fatty acid is bonded to the amino group of sphingosine or phytosphingosine, an amino alcohol with 18 carbon atoms, via an acid amide bond (ceramide), and further, a phosphoric or phosphonic acid is bonded to the hydroxyl group, and a base such as choline is further bonded to this acid. Examples include sphingomyelin, which is present in large quantities in the myelin sheath of animal nerves, and ceramide-phosphonic acid derivatives (such as ceramide aminoethylphosphonic acid).

[0019] The phospholipid is preferably lecithin, which is a type of glycerophospholipid, from the viewpoint of facilitating dispersion.

[0020] Lecithin exists in all cells of animals and plants in nature, and is a major component of biomembranes. Therefore, it is possible to extract lecithin from any animal or plant. Industrially, lecithin is obtained from soybeans, sunflowers, and egg yolks. Lecithin derived from soybeans is called soybean lecithin, lecithin derived from sunflowers is called sunflower lecithin, and lecithin derived from egg yolks is called egg yolk lecithin.

[0021] Soybean lecithin is produced by drying and refining the by-product of soybean oil refining process. Normally, paste-type lecithin with a phospholipid content of 70% or less by mass contains about 30% by mass of soybean crude oil, and because it is inexpensive, this paste-type lecithin is mostly used, especially in the food industry. In recent years, due to the physiological activity of phospholipids themselves and more advanced needs, technologies such as advanced purification, fractionation, modification, and enzymatic decomposition have been added, and various lecithin groups with different performance and functions have been produced.

[0022] Highly refined lecithin is obtained by de-oiling the above-mentioned paste-like lecithin with a solvent such as acetone to produce a powder, and generally has a lecithin content of 90% by mass or more. Examples of this highly refined lecithin include Phospholipon 20 (Lipoid), Lesion P (Riken Vitamin Co., Ltd.), SLP White (Tsuji Oil Mills Co., Ltd.), and Emulmetic 300 (Lucas Meyer Cosmetics).

[0023] Fractionated lecithin is obtained by increasing the content of specific phospholipids by utilizing the difference in solubility in various solvents or by performing operations such as distillation on the above-mentioned highly purified lecithin, and generally, products with increased phosphatidylcholine content are commercially available. Examples of phosphatidylcholine content (PC content) include Phospholipon 50 (PC content: 45% by mass), Phospholipon 85G (PC content: 80% by mass), Phospholipon 90G (PC content: 94% by mass) (all from Lipoid Co., Ltd.), Emermetic 900 (PC content: 50% by mass), Emermetic 930 (PC content: 95% by mass) (all from Lucas Meyer Cosmetics Co., Ltd.), SLP-PC70 (PC content: 70% by mass), SLP-PC90 (PC content: 90% by mass) (all from Tsuji Oil Mills Co., Ltd.), etc.

[0024] Modified lecithin can be broadly classified into hydrogenated lecithin and enzymatically decomposed lecithin.

[0025] Among these, hydrogenated lecithin is a lecithin in which unsaturated fatty acids in the lecithin structure are converted to saturated fatty acids through hydrogenation treatment to improve oxidation and light stability. The iodine value is used as an index to indicate the degree of hydrogenation treatment. Normally, the iodine value of unhydrogenated lecithin is 60 to 120, but this value approaches zero through hydrogenation. Commercially available hydrogenated lecithin has a value of 10 or less. Examples of hydrogenated lecithin include Emulmetic 320 (Lucas Meyer Cosmetics Co., Ltd.), SLP White H (Tsuji Oil Mills Co., Ltd.), etc. Examples of lecithin that have been hydrogenated after increasing the phosphatidylcholine content include Emulmetic 950 (Lucas Meyer Cosmetics Co., Ltd.), SLP-PC92H (Tsuji Oil Mills Co., Ltd.), and Phospholipon 90H (Lipoid Co., Ltd.).

[0026] On the other hand, enzymatically decomposed lecithin is obtained by selectively decomposing the ester bond of the fatty acid at the second position, which is usually bound to glycerin, using an enzyme, and is called lysolecithin to distinguish it from normal lecithin. Compared to the original lecithin, lysolecithin has improved water solubility and generally improved dispersibility. This enzymatic decomposition process is usually performed on the original paste-like lecithin, which is then highly refined, but sometimes the enzymatic decomposition process is performed on fractionated lecithin. A typical example of lysolecithin is SLP White Lyso (manufactured by Tsuji Oil Mills Co., Ltd.).

[0027] In the present invention, any of the above lecithins can be used. From the viewpoint of stability over time, however, among the above lecithins, lecithins having a phospholipid content of 70% by mass or more are preferred, and lecithins having a phospholipid content of 90% by mass or more are even more preferred.

[0028] Furthermore, the phosphatidylcholine content in the phospholipid is preferably in the range of 1 to 60% by mass, and lecithin in which the phosphatidylcholine content in the phospholipid is in the range of 1 to 40% by mass is more preferable.

[0029] (b) The phospholipid is preferably lecithin that has not been substantially subjected to hydrogenation treatment. It is preferable that the phospholipid contains lecithin having an iodine value of preferably 10 or more, more preferably 50 or more, in terms of exhibiting good dispersibility.

[0030] Furthermore, it is preferable that the (b) phospholipid contains lecithin having a phosphatidylcholine content of 1% by mass or more and 40% by mass or less in terms of the stability over time of the dispersion composition.

[0031] The content of phospholipid or lecithin in the dispersion composition is preferably 0.1% by mass to 10.0% by mass, more preferably 0.2% by mass to 8.0% by mass, and even more preferably 1% by mass to 4% by mass. By making the content of phospholipid 0.1% by mass or more, the dispersion stability of the dispersion composition tends to be better. In addition, by making the content of phospholipid 10.0% by mass or less, the excess phospholipid does not crosslink and aggregate the dispersed particles to destabilize them, and the dispersion stability of the dispersion composition is obtained.

[0032] In terms of stability over time, the mass ratio of (b) / (a) is 0.01 or more and 8.0 or less. If the mass ratio of (b) / (a) is less than 0.01, the dispersion of the dispersed particles is insufficient and the stability over time is low. If the mass ratio of (b) / (a) is more than 8.0, the dispersed particles become unstable due to the excess phospholipid, and the stability over time of the dispersion composition is impaired.

[0033] (c) Examples of polyhydric alcohols include propylene glycol, butylene glycol, dipropylene glycol, glycerin, diglycerin, ethylene glycol, polyethylene glycol, pentylene glycol, hexanediol, octanediol, etc. These polyhydric alcohols can be used alone or in the form of a mixture of two or more kinds.

[0034] (c) The polyhydric alcohol preferably contains a dihydric or trihydric alcohol, since it has the effect of penetrating between the lumps of the dispersion in water and thereby aiding in fine dispersion. Examples of the dihydric alcohol include ethylene glycol, propylene glycol, butylene glycol, pentylene glycol, and hexanediol. Examples of the trihydric alcohol include glycerin.

[0035] From the viewpoint of the stability over time of the dispersion, the (c) polyhydric alcohol preferably contains at least one selected from the group consisting of propylene glycol, butylene glycol, dipropylene glycol, glycerin, and diglycerin.

[0036] In order to improve the temporal stability of the dispersion composition, the content of the (c) polyhydric alcohol in the dispersion composition is preferably 0.1% by mass to 80.0% by mass, and more preferably 1.0% by mass to 70% by mass, relative to the total amount of the composition.

[0037] The dispersion composition of the present invention preferably contains water. The content of water in the dispersion composition is more preferably 1% by mass to 80% by mass, and in order to achieve antiseptic properties without a preservative, it is more preferably 10% by mass to 50% by mass, and even more preferably 20% by mass to 40% by mass.

[0038] The dispersion composition of the present invention may contain one or more additives, such as various medicinal ingredients, preservatives, colorants, pH adjusters, pH buffers, UV absorbers, moisturizers, preservatives, antioxidants, thickeners, fragrances, colorants, powders, and chelating agents, depending on the intended use.

[0039] The average particle size of the dispersed particles contained in the dispersion composition of the present invention is not particularly limited, but from the viewpoint of the dispersion stability and the stability over time of the dispersion composition, it is preferably on the order of nanometers (less than 1000 nm), preferably 500 nm or less, and more preferably 200 nm or less. The lower limit of the average particle size of the dispersed particles contained in the dispersion composition is not particularly limited, but can be, for example, 0.8 nm or more.

[0040] The average particle size of the dispersed particles in the present invention means the volume average particle size of the dispersed particles present in the dispersion composition. The average particle size of the dispersed particles contained in the dispersion composition of the present invention can be determined by a known method such as an electron microscope, centrifugal sedimentation method, liquid exclusion chromatography method, laser scattering diffraction method, or dynamic light scattering method. From the viewpoint of accuracy and ease of measurement, it is preferable to measure using the dynamic light scattering method.

[0041] In this specification, "stability over time" can be evaluated by measuring the change in turbidity before and after the passage of time, the rate of change in average particle size, or both.

[0042] The method for producing the dispersion composition of the present invention is not particularly limited, and can be produced according to a known method.For example, a method including: a) dissolving an aqueous component in water or an aqueous medium to obtain an aqueous composition; b) mixing or dissolving an oily component to obtain an oily composition; c) mixing the aqueous composition and the oily composition under stirring to disperse, and obtaining a dispersion composition is preferred.

[0043] As a means for dispersing the suspension obtained by the mixing process into fine particles of 1 micron or less, high-pressure dispersion is preferred. The high-pressure dispersion process is carried out at a temperature of 20°C to 80°C and a pressure of 50 MPa or more. By passing through such high-pressure dispersion treatment, finely dispersed particles having a volume average particle size in the range of 10 nm to 500 nm can be obtained.

[0044] A high-pressure homogenizer is used as a dispersion means applied to the high-pressure dispersion step. A high-pressure homogenizer can apply a larger shear force than a stirring method, making it possible to reduce the size of the particles. Various high-pressure homogenizers are commercially available.

[0045] High-pressure homogenizers are roughly divided into chamber-type high-pressure homogenizers with a fixed throttle section and homogenous valve-type high-pressure homogenizers that control the throttle opening. Examples of the former chamber-type high-pressure homogenizers include Microfluidizer (manufactured by Microfluidics), Nanomizer (manufactured by Yoshida Kikai Kogyo Co., Ltd.), and Starburst (manufactured by Sugino Machine Co., Ltd.). Examples of the latter homogenous valve-type high-pressure homogenizers include Gaulin-type homogenizers (manufactured by APV), Lanier-type homogenizers (manufactured by Lanier), high-pressure homogenizers (manufactured by Niro Soavi), homogenizers (manufactured by Sanwa Kikai Co., Ltd.), high-pressure homogenizers (manufactured by Izumi Food Machinery Co., Ltd.), and ultra-high-pressure homogenizers (manufactured by Ika Co., Ltd.).

[0046] In the present invention, the phospholipid may be added after the dispersion step of the phospholipid solution, but it is more preferable to add the phospholipid before the dispersion step in order to impart dispersibility and stability over time.

[0047] In this specification, the "stability over time" can be evaluated by measuring the change in turbidity before and after the passage of time, the rate of change in average particle size, or both.

[0048] The dispersion composition of the present invention may be a cosmetic composition or a pharmaceutical composition. Pharmaceutical compositions include pharmaceutical products and quasi-drugs.

[0049] When preparing a cosmetic composition, the form is not particularly limited, and it can be in any form, such as a solution, emulsion, powder, water-oil two-layer system, water-oil-powder three-layer system, gel, solid such as tablet, aerosol, mist, capsule and sheet. The cosmetic composition can also be in any product form, such as skin care cosmetics such as face wash, makeup remover, lotion, beauty essence, pack, emulsion, cream, and sunscreen, makeup cosmetics such as foundation, makeup base, lipstick, eye shadow, eyeliner, mascara, eyebrow, blusher, and nail enamel, hair cosmetics such as hair shampoo, hair rinse, hair styling agent, hair dye, and hair growth agent, body cleansers such as soap, body soap, deodorant cosmetics, and bath agents, oral cosmetics such as dentifrice, mouthwash, and oral paste, and aromatic cosmetics such as perfume. In addition, this cosmetic may be either a cosmetic or a quasi-drug under the Pharmaceutical Affairs Act of Japan.

[0050] In terms of the use of the henbit or an extract thereof, the dispersion composition is preferably for use in cosmetics, oral cosmetics, or hair growth agents.

[0051] The cosmetic composition can be produced by a conventional method by blending, as necessary, other ingredients commonly used in cosmetics, quasi-drugs, and pharmaceuticals, for example, active ingredients such as moisturizers, whitening agents, anti-inflammatory agents, blood circulation promoters, and antiseborrheic agents, as well as powdered ingredients, oils and fats, fatty acids, alcohols, esters, silicones, surfactants, water-soluble polymers, thickeners, film-forming agents, UV absorbers, sequestering agents, pH adjusters, antioxidants, preservatives, fragrances, water, and other additives. Pharmaceutical compositions are usually prepared as formulations containing active ingredients and preferably pharma- ceutical acceptable carriers. Pharmaceutically acceptable carriers refer to inert, non-toxic, solid or liquid fillers, diluents or encapsulating materials that do not react with active ingredients. Examples of carriers include solvents or dispersion media such as water, ethanol, polyols (e.g., propylene glycol, butylene glycol, glycerin, polyethylene glycol, etc.), suitable mixtures thereof, vegetable oils, etc.

[0052] The pharmaceutical composition is administered orally or parenterally, for example, into the mouth, into the skin, subcutaneously, into the mucosa, into the eyes, and into the nasal cavity. Oral formulations include tablets, granules, fine granules, powders, capsules, chewables, pellets, syrups, liquids, suspensions, and inhalants. Parenteral formulations include suppositories, retention enemas, eye drops, nasal drops, pessaries, injections, mouthwashes, and skin topicals or transdermal formulations such as ointments, liquids, creams, gels, sprays, controlled release patches, and patches. Alternatively, the pharmaceutical composition of the present invention may be administered parenterally in the form of a sustained release subcutaneous implant, or in the form of a targeted delivery system (e.g., monoclonal antibodies, vector delivery, ion injection, polymer matrix, liposomes, and microspheres).

[0053] The pharmaceutical composition may further contain additives commonly used in the pharmaceutical field. Such additives include, for example, excipients, binders, disintegrants, lubricants, antioxidants, colorants, flavoring agents, etc., and can be used as needed. Furthermore, other additives or drugs, such as antacids and gastric mucosa protectants, may be added as needed. In order to achieve sustained release so as to act for a long time, the composition may be coated with a known retardant, etc.

[0054] The pharmaceutical composition and cosmetic composition can be applied in the form of an oral composition, an external composition, an internal composition, etc., and are preferably used in the form of an external preparation for skin or an external composition for skin. When used in the form of an external preparation for skin or an external composition for skin, in addition to the dispersion composition of the present invention, components used in normal external preparations for skin, such as surfactants, oily substances, polymeric compounds, preservatives, various medicinal ingredients, powders, ultraviolet absorbers, pigments, fragrances, colorants, emulsion stabilizers, radical scavengers, pH adjusters, etc., can be appropriately blended.

[0055] The dispersion composition of the present invention can be produced according to a known method. For example, the above-mentioned dispersion composition can be obtained by diluting it with purified water or the like so that the content is 0.001% by mass to 50% by mass, etc., based on the total mass of the cosmetic (e.g., a composition for external use on skin). From the viewpoint of suppressing the turbidity of the cosmetic, it is preferable to reduce the amount of the dispersion composition blended in the cosmetic. From this viewpoint, the blending amount of the dispersion composition in the cosmetic of the present invention is preferably 30% by mass or less, more preferably 20% by mass or less, based on the total mass of the cosmetic.

[0056] The subject to which the dispersion composition of the present invention is administered is preferably a warm-blooded vertebrate, more preferably a mammal.In this specification, the mammal includes, for example, humans and non-human mammals such as monkeys, mice, rats, rabbits, dogs, cats, cows, horses, and pigs.The dispersion composition of the present invention is suitable for administration to primates such as humans and monkeys, especially humans.

[0057] The following examples are intended for illustrative purposes only and are not intended to limit the scope of the present invention in any way. Unless otherwise specified, reagents are commercially available or are obtained or prepared according to conventional techniques or procedures known in the art. EXAMPLES

[0058] Test Example 1: Preparation of Dispersion Composition 1. Preparation of Dispersion Composition <Preparation of Dispersion Composition of Example 1> (c) 67.5 g of glycerin and 15 g of purified water were mixed, and (b) 2.5 g of lecithin (trade name: SLP-White; manufactured by Tsuji Oil Mills) was added thereto and stirred and dissolved at 70°C for 30 minutes. Then, 15 g of (a) ketto extract (trade name) (manufactured by Matsuura Pharmaceutical Co., Ltd.: containing 5% ketto) was added and mixed uniformly to obtain a suspension. The obtained suspension was passed through an ultra-high pressure dispersing machine (trade name: Starburst Mini, manufactured by Sugino Machine Co., Ltd.) three times at a pressure of 200 MPa while maintaining the temperature at 60°C, to perform a high-pressure dispersion process, and an aqueous dispersion called the dispersion of Example 1 was obtained.

[0059] <Preparation of Dispersion Compositions of Examples 2 to 12 and Comparative Examples 1 to 4> The dispersions of Examples 2 to 12 and Comparative Examples 1 to 4 were prepared in the same manner as in Example 1, except that the formulations were as shown in Table 1 (in Table 1, the unit of each component is mass (g). PC: phosphatidylcholine SLP White Unmodified, unfractionated lecithin, PC content 28% Tsuji Oil Mills SLP-PC70 Unmodified, fractionated lecithin, PC content 70% Tsuji Oil Mills LIPOID P-70 Unmodified, fractionated lecithin, PC content 70% Lipoid Corporation LIPOID P-45 Unmodified, fractionated lecithin, PC content 45% Lipoid Corporation Reciprate SOY-75H Hydrogenated, fractionated lecithin, PC content 70% Technoble Co., Ltd. SLP White H Hydrogenated, unfractionated lecithin, PC content 28% Tsuji Oil Mills SLP White Lyso Enzyme-treated, unfractionated lecithin, PC content 28% Tsuji Oil Mills SLP-PI Powder Unmodified, fractionated lecithin, PC content 18% Tsuji Oil Mills HCO-60 NIKKOL HCO-60 Polyoxyethylene (60) hydrogenated castor oil Nikko Chemicals Co., Ltd. 1,3-BG 1,3-Butylene glycol DPG Dipropylene Glycol

[0060] 2. Evaluation of the temporal stability of the dispersion composition <Evaluation of initial stability> The obtained dispersions of Examples 1 to 12 and Comparative Examples 1 to 4 were each diluted 10-fold with purified water, and the volume average particle diameter of the dispersed particles was measured using a dynamic light scattering particle size analyzer (product name: Nanotrac UPA, manufactured by Nikkiso Co., Ltd.), and evaluated together with the transparency by visual observation.

[0061] <Evaluation of stability over time> After storing each dispersion at 40° C. for 2 months, the particle size of the dispersed particles was measured in the same manner as in the particle size measurement method described above, and the particle size was evaluated together with visual transparency and precipitation (phase separation). The initial stability and stability over time were ranked as follows: A to D are acceptable, and E is unacceptable.

[0062] The dispersions of Examples 1 to 12 were excellent in stability even after storage at 40° C. for 2 months, whereas the dispersions of Comparative Examples 1 to 4 underwent phase separation.

[0063] A: Average particle size less than 200 nm, good transparency, no phase separation B: Average particle size 200 nm or more and less than 500 nm, slight turbidity, no phase separation C: Average particle size 200 nm or more and less than 500 nm, moderate turbidity, no phase separation D: Average particle size 500nm or more, high turbidity, no phase separation E. Phase separation (precipitate or floating matter)

[0064] [Table 1]

[0065] Test Example 2: Preparation of oral paste An oral paste was prepared using the composition shown in Table 2 as a skin topical agent, and it was confirmed that not only the dispersion but also the formulation could be stably prepared.

[0066] [Table 2]

[0067] Test Example 3: Manufacturing of mouthwash A mouthwash was prepared as an external preparation for the skin with the composition shown in Table 3, and it was confirmed that it could be prepared stably.

[0068] [Table 3]

[0069] Test Example 4: Production of lotion A skin lotion was prepared with the composition shown in Table 4 as an external skin agent, and it was confirmed that it could be prepared stably.

[0070] [Table 4]

[0071] Test Example 5: Production of hair growth agent A hair growth agent was prepared as an external skin agent with the composition shown in Table 5, and it was confirmed that it could be prepared stably.

[0072] [Table 5]

Claims

1. (a) henbit or an extract thereof; (b) a phospholipid, and (c) A dispersion composition comprising a polyhydric alcohol, the mass ratio of (b) / (a) being 0.01 or more and 8.0 or less.

2. The dispersion composition of claim 1 , wherein the (b) phospholipid comprises lecithin.

3. The dispersion composition according to claim 1, characterized in that the (b) phospholipid contains lecithin that has not been substantially subjected to hydrogenation treatment.

4. The dispersion composition according to claim 1 , wherein the phospholipid (b) contains lecithin having a phosphatidylcholine content of 1% by mass or more and 40% by mass or less.

5. 2. The dispersion composition according to claim 1, wherein the (c) polyhydric alcohol comprises a dihydric or trihydric alcohol.

6. 2. The dispersion composition according to claim 1, wherein the polyhydric alcohol (c) comprises at least one selected from the group consisting of propylene glycol, butylene glycol, dipropylene glycol, glycerin, and diglycerin.

7. 2. The dispersion composition according to claim 1, wherein the average particle size of the dispersed particles is 500 nm or less.

8. The dispersion composition according to any one of claims 1 to 7, which is an external preparation for the skin.

9. The dispersion composition according to any one of claims 1 to 7, which is for use in a cosmetic composition, an oral composition, or a hair growth agent.

10. A medicament comprising the dispersion composition according to claim 8 or 9.

Images